Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram (Lexapro) for Depression MS or ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 70 years of age with documented ALS or MS,~* DSM-IV episode of non-psychotic Major Depression,~* ≥14 score on the 17-item HAM-D,~* Ability to give informed consent.~Exclusion Criteria:~* History of psychotic disorders,~* Psychotic depression,~* Bipolar depression,~* Suicide risk,~* History of substance abuse in the previous 6 months,~* History of unstable medical disorders,~* Pregnancy or planning for pregnancy,~* Severity of ALS or MS that limits participating in the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): All patients will receive escitalopram 20 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).